Developmental trajectory of individuals with Pelizaeus-Merzbacher Disease (PMD)
Anjana Sevagamoorthy(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Ylenia Vaia, Eloise Uebergang(Murdoch Children's Research Institute), Francesco Gavazzi(Children's Hospital of Philadelphia), Amytice Mirchi(McGill University), Russel D'Aiello(Children's Hospital of Philadelphia), Enrico Bertini(Bambino Gesù Children's Hospital), Gabrielle Sudilovsky, Amy Pizzino(Children's Hospital of Philadelphia), Kaleb Kelley, Sarah Woidill, Chloe Cunningham, Fabio Bruschi, Davide Tonduti(Luigi Sacco Hospital), Nicole I. Wolf(Amsterdam Neuroscience), Jacapo Sartorelli(Bambino Gesù Children's Hospital), Chihiro Abe-Hatano(National Center of Neurology and Psychiatry), Justine Schults(Children's Hospital of Philadelphia), Johanna L. Schmidt(Children's Hospital of Philadelphia), Laura A. Adang(Children's Hospital of Philadelphia), Geneviève Bernard(McGill University), Ken Inoue(National Center of Neurology and Psychiatry), Francesco Nicita(Sapienza University of Rome)
Cited by 0
Related Papers
Characterization of human disease phenotypes associated with mutations in <i>TREX1</i>, <i>RNASEH2A</i>, <i>RNASEH2B</i>, <i>RNASEH2C</i>, <i>SAMHD1</i>, <i>ADAR</i>, and <i>IFIH1</i>
|American Journal of Medical Genetics Part A|2015|617
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441
Janus Kinase Inhibition in the Aicardi–Goutières Syndrome
|New England Journal of Medicine|2020|201
Genetic and phenotypic spectrum associated with IFIH1 gain‐of‐function
|Human Mutation|2020|115